Jason Lettmann, ALX Oncology CEO (Lightstone Ventures)
October 3, 2023 07:34 AM EDTUpdated 11:24 AM
R&D

Up­dat­ed: In turn­around, ALX On­col­o­gy’s CD47 block­er shows ef­fi­ca­cy in gas­tric can­cer tri­al

Lei Lei Wu

News Reporter

Don’t write off CD47 just yet.

ALX On­col­o­gy said that 52% of gas­tric can­cer pa­tients who re­ceived its an­ti-CD47 drug evor­pacept in com­bi­na­tion with a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times